References
- BoyerEWShannonMThe serotonin syndromeN Engl J Med2005352111112112015784664
- DunkleyEJIsbisterGKSibbrittDDawsonAHWhyteIMThe Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicityQJM200396963564212925718
- American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR)Washington DCAmerican Psychiatric Association2000795798
- IsbisterGKBuckleyNAWhyteIMSerotonin toxicity: a practical approach to diagnosis and treatmentMed J Aust2007187636136517874986
- HerrKDNemeroffCBParoxetineSchatzbergAFNemeroffCBThe American Psychiatric Publishing Textbook of Psychopharmacology3rdArlington, VAAmerican Psychiatric Publishing2004259281
- OdagakiYToyoshimaR5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranesClin Exp Pharmacol Physiol2007345–646246617439416
- IshibashiTOhnoYPerospirone hydrochloride: the novel atypical antipsychotic agent with high affinities for 5-HT2, D2 and 5-HT1A receptorsBiogenic Amines200418307311
- SchotteAJanssenPFGommerenWRisperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindingPsychopharmacology (Berl)19961241–257738935801
- Newman-TancrediAThe importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectivesCurr Opin Investig Drugs2010117802812
- MeltzerHYSumiyoshiTDoes stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?Behav Brain Res200819519810218707769
- SatoSMizukamiKMoroKTanakaYAsadaTEfficacy of perospirone in the management of aggressive behavior associated with dementiaProg Neuropsychopharmacol Biol Psychiatry200630467968316581169
- SmithLMPeroutkaSJDifferential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndromePharmacol Biochem Behav1986246151315192942947
- NisijimaKShiodaKIwamuraTNeuroleptic malignant syndrome and serotonin syndromeProg Brain Res20071628110417645916
- Abdel-FattahAFMatsumotoKel-HadyKAWatanabeH5-HT1A and 5-HT2 receptors mediate hypo- and hyperthermic effects of tryptophan in pargyline-pretreated ratsPharmacol Biochem Behav19955223793848577805
- NisijimaKYoshinoTYuiKKatohSPotent serotonin (5-HT) (2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndromeBrain Res20018901233111164765
- SlettedalJKNilssenDOMagelssenMLøbergEMMaehlenJBrain pathology in fatal serotonin syndrome: presentation of two casesNeuropathology201131326527020880320
- DalpiazAGessiSBoreaPAGilliGBinding thermodynamics of serotonin to rat-brain 5-HT1A, 5HT2A and 5-HT3 receptorsLife Sci19955712PL141PL1467674802
- TanakaANagamatsuTYamaguchiMMyoclonus after dextromethorphan administration in peritoneal dialysisAnn Pharmacother2011451e121228393
- KalueffAVLaPorteJLMurphyDLPerspectives on genetic animal models of serotonin toxicityNeurochem Int2008524–564965817935833
- LauterbachECFluoxetine, buspirone, myoclonus, and dystoniaAm J Psychiatry19951521116977485652
- ManosGHPossible serotonin syndrome associated with buspirone added to fluoxetineAnn Pharmacother2000347–887187410928399
- OdagakiYAtypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?Curr Drug Saf200941849319149529
- TrivediMHFavaMWisniewskiSRSTAR*D Study TeamMedication augmentation after the failure of SSRIs for depressionN Engl J Med2006354121243125216554526
- CarpenterLLYasminSPriceLHA double-blind, placebo-controlled study of antidepressant augmentation with mirtazapineBiol Psychiatry200251218318811822997
- WorthingtonJJ3rdKinrysGWygantLEPollackMHAripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patientsInt Clin Psychopharmacol200520191115602109
- HeinrichTBöttcherHGerickeRSynthesis and structure – activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitorsJ Med Chem200447194684469215341484
- Bang-AndersenBRuhlandTJørgensenMDiscovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorderJ Med Chem20115493206322121486038